Mild to moderate Crohn's disease: An evidence-based treatment algorithm

Drugs

Volumn 68, Issue 17, 2008, Pages 2419-2425

  Wong, Karen ^a   Bressler, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Budesonide, therapeutic use; Crohn's disease, treatment; Mesalazine, therapeutic use; Sulfasalazine, therapeutic use

Indexed keywords

ANTIINFECTIVE AGENT; BUDESONIDE; CIPROFLOXACIN; MESALAZINE; METRONIDAZOLE; PREBIOTIC AGENT; PREDNISOLONE; PROBIOTIC AGENT; RIFAXIMIN; SALAZOSULFAPYRIDINE;

ALGORITHM; BLOOD DYSCRASIA; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG INDICATION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; INTERSTITIAL NEPHRITIS; LACTOBACILLUS; MAINTENANCE THERAPY; PANCREATITIS; PRACTICE GUIDELINE; REVIEW; SACCHAROMYCES BOULARDII; SKIN MANIFESTATION;

ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; LACTOBACILLUS; PROBIOTICS; SACCHAROMYCES;

EID: 56549109219     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868170-00002     Document Type: Review

References (35)

1. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity and endoscopic severity and biologic parameters in colonic or ileocolonic Crohn's disease: a prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35: 231-5
2. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with crohn's disease. Gastroenterology 2002; 122: 512-30
3. Hanauer SB, Sandborn W, for the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001; 96 (3): 635-43
4. Silverstein M, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's Disease: Markov Model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57
5. Loftus Jr EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60
6. Metge CJ, Blanchard JF, Peterson S, et al. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Am J Gastroenterol 2001; 96 (12): 3348-55
7. Khan A, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977 Oct; II (8044): 892-5
8. Doering J, Begue B, Lentze JM, et al. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 2004 Nov; 53 (11): 1632-8
9. Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979 Oct; 77 (4 Pt 2): 847-69
10. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984 Feb; 86 (2): 249-66
11. Van Hees PA, Van Lier HJ, Van Eltersen PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981 May; 22 (5): 404-9
12. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993 May; 104 (5): 1293-301
13. Hanauer SB, Stomberg U. Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2: 379-88
14. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997 Apr; 112 (4): 1069-77
15. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 2001 Oct; 49 (4): 552-6
16. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology 1992 Aug; 103 (2): 363-8
17. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn. Cochrane Database Syst Rev 2005 Jan; 25 (1): CD003715
18. Ransford RA, Langman MJ. Sulphasalazine and mesalamine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicine. Gut 2002 Oct; 51 (4): 536-9
19. Logan RF, van Staa TP. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines [letter]. Gut 2003 Oct; 52 (10): 1530
20. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996 Jan; 110 (1): 45-51
21. Tremaine WJ, Hanauer SB, Winston BD, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002 Jul; 97 (7): 1748-54
22. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998 Aug 6; 339 (6): 370-4
23. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994 Sept 29; 331 (13): 842-5
24. Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002 Aug; 16 (8): 1509-17
25. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocecal Crohn's disease: a placebo controlled one year study. Gut 1996; 39: 82-6
26. Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn's disease: results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998; 12: 175-83
27. Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 363-71
28. Sandborn WJ, Lofberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005 Aug; 100 (8): 1780-7
29. Sutherland L, Singleton J, Sessions J, et al. Double-blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991 Sep; 32 (9): 1071-5
30. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002 Jul; 123 (1): 33-40
31. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006 Apr 15; 23 (8): 1117-25
32. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci July 2000; 45 (7): 1462-4
33. Zocco MA. Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease [abstract]. Gastroenterology 2003 Apr; 124 (4 Suppl. 1): A201
34. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn. Cochrane Database Syst Rev 2006 Oct 18; (4): CD004826
35. Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006 Mar; 55 (3): 348-55